Tissue deiodinase activity during prolonged critical illness: Effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone-releasing peptide-2

Endocrinology

Volumn 146, Issue 12, 2005, Pages 5604-5611

  Debaveye, Yves ^a   Ellger, Björn ^a,b   Mebis, Liese ^a   Van Herck, Erik ^a   Coopmans, Willy ^a   Darras, Veerle ^a   Van Den Berghe, Greet ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DEIODINASE; LIOTHYRONINE; LIVER ENZYME; PRALMORELIN; PROTIRELIN; SODIUM CHLORIDE; THYROID HORMONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BURN; CATALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CRITICAL ILLNESS; ENZYME ACTIVITY; IN VIVO STUDY; KIDNEY; LIVER; MALE; MUSCLE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RANDOMIZATION;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CHRONIC DISEASE; CRITICAL ILLNESS; DRUG COMBINATIONS; GASES; GROWTH HORMONE; HEMOGLOBINS; INSULIN-LIKE GROWTH FACTOR I; IODIDE PEROXIDASE; ISOENZYMES; LIVER; MALE; OLIGOPEPTIDES; PARENTERAL NUTRITION; RABBITS; THYROID HORMONES; THYROTROPIN-RELEASING HORMONE;

EID: 27844520169     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2005-0963     Document Type: Article

References (43)

1. Van den Berghe G, de Zegher F, Bouillon R 1998 Acute and prolonged critical illness as different neuroendocrine paradigms. J Clin Endocrinol Metab 83:1827-1834
2. Van den Berghe G 2002 Dynamic neuroendocrine responses to critical illness. Front Neuroendocrinol 23:370-391
3. Van den Berghe G, de Zegher F, Veldhuis JD, Wouters P, Awouters M, Verbruggen W, Schetz M, Verwaest C, Lauwers P, Bouillon R, Bowers CY 1997 The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion. J Clin Endocrinol Metab 82:590-599
4. Van den Berghe G, de Zegher F, Bouillon R 1998 The somatotrophic axis in critical illness: effects of growth hormone secretagogues. Growth Horm IGF Res 8(Suppl B):153-155
5. Ellger B, Debaveye Y, Van den Berghe G 2005 Endocrine interventions in the ICU. Eur J Intern Med 16:71-82
6. Van den Berghe G, de Zegher F, Baxter RC, Veldhuis JD, Wouters P, Schetz M, Verwaest C, Van der Vorst E, Lauwers P, Bouillon R, Bowers CY 1998 Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues. J Clin Endocrinol Metab 83:309-319
7. Van den Berghe G, Baxter RC, Weekers F, Wouters P, Bowers CY, Iranmanesh A, Veldhuis JD, Bouillon R 2002 The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone. Clin Endocrinol (Oxf) 56:655-669
8. Van den Berghe G, Wouters P, Weekers F, Mohan S, Baxter RC, Veldhuis JD, Bowers CY, Bouillon R 1999 Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness. J Clin Endocrinol Metab 84:1311-1323
9. Larsen PR, Silva JE, Kaplan MM 1981 Relationships between circulating and intracellular thyroid hormones: physiological and clinical implications. Endocr Rev 2:87-102
10. Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR 2002 Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev 23:38-89
11. St Germain DL, Galton VA 1997 The deiodinase family of selenoproteins. Thyroid 7:655-668
12. Peeters RP, Wouters PJ, Kaptein E, van Toor H, Visser TJ, Van den Berghe G 2003 Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. J Clin Endocrinol Metab 88:3202-3211
13. 3 are prognostic markers in critically ill patients and are associated with post-mortem tissue deiodinase activities. J Clin Endocrinol Metab 90:4559-4565
14. Weekers F, Michalaki M, Coopmans W, Van Herck E, Veldhuis JD, Darras VM, Van den Berghe G 2004 Endocrine and metabolic effects of growth hormone (GH) compared with GH-releasing peptide, thyrotropin-releasing hormone, and insulin infusion in a rabbit model of prolonged critical illness. Endocrinology 145:205-213
15. Darras VM, Berghman LR, Vanderpooten A, Kuhn ER 1992 Growth hormone acutely decreases type III iodothyronine deiodinase in chicken liver. FEBS Lett 310:5-8
16. Weekers F, Van Herck E, Coopmans W, Michalaki M, Bowers CY, Veldhuis JD, Van den Berghe G 2002 A novel in vivo rabbit model of hypercatabolic critical illness reveals a biphasic neuroendocrine stress response. Endocrinology 143:764-774
17. Verhaeghe J, Suiker AM, Visser WJ, Van Herck E, Van Bree R, Bouillon R 1992 The effects of systemic insulin, insulin-like growth factor-I and growth hormone on bone growth and turnover in spontaneously diabetic BB rats. J Endocrinol 134:485-492
18. Van der Geyten S, Van den Eynde I, Segers IB, Kuhn ER, Darras VM 2002 Differential expression of iodothyronine deiodinases in chicken tissues during the last week of embryonic development. Gen Comp Endocrinol 128:65-73
19. Kuhn ER, De Groef B, Grommen SV, Van der Geyten S, Darras VM 2004 Low submetamorphic doses of dexamethasone and thyroxine induce complete metamorphosis in the axolotl (Ambystoma mexicanum) when injected together. Gen Comp Endocrinol 137:141-147
20. Schatz DL, Sheppard RH, Steiner G, Chandarlapaty CS, de Veber GA 1969 Influence of heparin on serum free thyroxine. J Clin Endocrinol Metab 29:1015-1022
21. Darras VM, Visser TJ, Berghman LR, Kuhn ER 1992 Ontogeny of type I and type III deiodinase activities in embryonic and posthatch chicks: relationship with changes in plasma triiodothyronine and growth hormone levels. Comp Biochem Physiol Comp Physiol 103:131-136
22. Darras VM, Kotanen SP, Geris KL, Berghman LR, Kuhn ER 1996 Plasma thyroid hormone levels and iodothyronine deiodinase activity following an acute glucocorticoid challenge in embryonic compared with posthatch chickens. Gen Comp Endocrinol 104:203-212
23. Wehmann RE, Gregerman RI, Burns WH, Saral R, Santos GW 1985 Suppression of thyrotropin in the low-thyroxine state of severe nonthyroidal illness. N Engl J Med 312:546-552
24. Van den Berghe G, de Zegher F, Veldhuis JD, Wouters P, Gouwy S, Stockman W, Weekers F, Schetz M, Lauwers P, Bouillon R, Bowers CY 1997 Thyrotrophin and prolactin release in prolonged critical illness: dynamics of spontaneous secretion and effects of growth hormone-secretagogues. Clin Endocrinol (Oxf) 47:599-612
25. 3) in systemic illnesses. J Clin Endocrinol Metab 41:1043-1049
26. Carter JN, Eastmen CJ, Corcoran JM, Lazarus L 1976 Inhibition of conversion of thyroxine to triiodothyronine in patients with severe chronic illness. Clin Endocrinol (Oxf) 5:587-594
27. Cobb WE, Reichlin S, Jackson IM 1981 Growth hormone secretory status is a determinant of the thyrotropin response to thyrotropin-releasing hormone in euthyroid patients with hypothalamic-pituitary disease. J Clin Endocrinol Metab 52:324-329
28. Kaptein EM, Feinstein EI, Nicoloff JT, Massry SG 1983 Serum reverse triiodothyronine and thyroxine kinetics in patients with chronic renal failure. J Clin Endocrinol Metab 57:181-189
29. Salvatore D, Bartha T, Harney JW, Larsen PR 1996 Molecular biological and biochemical characterization of the human type 2 selenodeiodinase. Endocrinology 137:3308-3315
30. Peeters RP, van den Beld AW, Attalki H, Toor H, de Rijke YB, Kuiper GG, Lamberts SW, Janssen JA, Uitterlinden AG, Visser TJ 2005 A new polymorphism in the type II deiodinase gene is associated with circulating thyroid hormone parameters. Am J Physiol 289:E75-E81
31. Steinsapir J, Bianco AC, Buettner C, Harney J, Larsen PR 2000 Substrate-induced down-regulation of human type 2 deiodinase (hD2) is mediated through proteasomal degradation and requires interaction with the enzyme's active center. Endocrinology 141:1127-1135
32. Huang SA, Fish SA, Dorfman DM, Salvatore D, Kozakewich HP, Mandel SJ, Larsen PR 2002 A 21-year-old woman with consumptive hypothyroidism due to a vascular tumor expressing type 3 iodothyronine deiodinase. J Clin Endocrinol Metab 87:4457-4461
33. Huang SA, Tu HM, Harney JW, Venihaki M, Butte AJ, Kozakewich HP, Fishman SJ, Larsen PR 2000 Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas. N Engl J Med 343:185-189
34. Richard K, Hume R, Kaptein E, Sanders JP, van Toor H, De Herder WW, den Hollander JC, Krenning EP, Visser TJ 1998 Ontogeny of iodothyronine deiodinases in human liver. J Clin Endocrinol Metab 83:2868-2874
35. Berry MJ, Kates AL, Larsen PR 1990 Thyroid hormone regulates type I deiodinase messenger RNA in rat liver. Mol Endocrinol 4:743-748
36. O'Mara BA, Dittrich W, Lauterio TJ, St Germain DL 1993 Pretranslational regulation of type I 5-deiodinase by thyroid hormones and in fasted and diabetic rats. Endocrinology 133:1715-1723
37. Vasilatos-Younken R, Zhou Y, Wang X, McMurtry JP, Rosebrough RW, Decuypere E, Buys N, Darras VM, Van Der Geyten S, Tomas F 2000 Altered chicken thyroid hormone metabolism with chronic GH enhancement in vivo: consequences for skeletal muscle growth. J Endocrinol 166:609-620
38. Moller J, Jorgensen JO, Moller N, Christiansen JS, Weeke J 1992 Effects of growth hormone administration on fuel oxidation and thyroid function in normal man. Metabolism 41:728-731
39. Jorgensen JO, Moller J, Laursen T, Orskov H, Christiansen JS, Weeke J 1994 Growth hormone administration stimulates energy expenditure and extrathyroidal conversion of thyroxine to triiodothyronine in a dose-dependent manner and suppresses circadian thyrotrophin levels: studies in GH-deficient adults. Clin Endocrinol (Oxf) 41:609-614
40. Martin D, Epelbaum J, Bluet-Pajot MT, Prelot M, Kordon C, Durand D 1985 Thyroidectomy abolishes pulsatile growth hormone secretion without affecting hypothalamic somatostatin. Neuroendocrinology 41:476-481
41. Bruhn TO, McFarlane MB, Deckey JE, Jackson IM 1992 Analysis of pulsatile secretion of thyrotropin and growth hormone in the hypothyroid rat. Endocrinology 131:2615-2621
42. Schmid C, Brandle M, Zwimpfer C, Zapf J, Wiesli P 2004 Effect of thyroxine replacement on creatinine, insulin-like growth factor 1, acid-labile subunit, and vascular endothelial growth factor. Clin Chem 50:228-231
43. Miell JP, Taylor AM, Zini M, Maheshwari HG, Ross RJ, Valcavi R 1993 Effects of hypothyroidism and hyperthyroidism on insulin-like growth factors (IGFs) and growth hormone- and IGF-binding proteins. J Clin Endocrinol Metab 76:950-955